Amlexanox

Drug Profile

Amlexanox

Alternative Names: Aftaid; Aphthasol; Aphtheal; Apthera; CHX 3673; Miraftil; OraDisc A

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Aminopyridines; Antiallergics; Small molecules
  • Mechanism of Action Cyclic AMP phosphodiesterase inhibitors; Histamine H1 receptor antagonists; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Aphthous stomatitis

Highest Development Phases

  • Marketed Aphthous stomatitis
  • Discontinued Mucositis

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top